Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 10/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492330 | 0.91 | PDE4A (0.49) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12856197 | 0.88 | QDPR (0.44) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10208059 | 0.86 | QDPR (0.70) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14747863 | 0.86 | CYP2C9 (0.47) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14747864 | 0.85 | PDE4A (0.43) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16553704 | 0.84 | QDPR (0.46) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1494013 | 0.83 | NR3C1 (0.64) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14864496 | 0.83 | PDE4B (0.39) | QDPRPDE4APDE4BPDE4CPDE4D | |
| Ammonia Solution, Strong SCHEMBL7288975 | 0.82 | NR3C1 (0.62) | QDPRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19288830 | 0.81 | HPGD (0.52) | QDPRPDE4BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-8481581-B2 | S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252828-B2 | S-triazolyl α-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8106205-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110313157-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-7858632-B2 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283301-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | QDPR 25/4885PDE4A 4367/4885PDE4B 4465/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | QDPR 25/4885PDE4A 4367/4885PDE4B 4465/4885 |
| US-20110313157-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | QDPR 25/4885PDE4A 4367/4885PDE4B 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.